Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3109 - ROR_ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non–small cell lung cancer: an open-label, multicenter Phase 1b trial

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

D Camidge

Citation

Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288

Authors

D.R. Camidge1, S.M. Gadgeel2, H.J. Wilkins3, G. Weems3, R. Santana-Davila4, M. Johnson5

Author affiliations

  • 1 Division Of Medical Oncology, University of Colorado Cancer Center, 80045 - Aurora/US
  • 2 Department Of Internal Medicine, University of Michigan, 48109-5942 - Ann Arbor/US
  • 3 Clinical Development, Lycera Corp., 19462 - Plymouth Meeting/US
  • 4 Medical Oncology, Seattle Cancer Care Alliance, Seattle/US
  • 5 Lung Cancer Program, Sarah Cannon Research Institute, Nashville/US
More

Resources

Abstract 3109

Background

The first-in-class, oral, small-molecule agonist of retinoic acid receptor–related orphan receptor γ (RORγ), LYC-55716, is an investigational agent under development as an immunotherapy for solid tumors. A Phase 1/2a trial demonstrated the safety of LYC-55716 as monotherapy and provided evidence of clinical activity, including a confirmed partial response in a patient with non–small cell lung cancer (NSCLC). Based on pre-clinical testing, the combination of RORγ agonist and a PD-1 inhibitor may enhance immune activation and the favorable effects of PD-1 inhibition on the tumor microenvironment. This ongoing open-label, multicenter Phase 1b trial is assessing the safety as well as clinical and biologic activity of LYC-55716 in combination with pembrolizumab (L+P) in patients with NSCLC.

Methods

A run-in cohort of patients (n = 3) is receiving L+P to monitor for safety signals. After determining a dose for further study, 1 main cohort (n = 15) will receive L+P until disease progression or unacceptable toxicity. Pre- and post-treatment biopsies will be obtained for patients in the main study cohort. Primary endpoints are safety (monitoring of adverse events, physical examination, lab results) and incidence of dose-limiting toxicities during the run-in period and ongoing treatment. Secondary endpoints include cellular and molecular immune response and biomarkers, objective response rate, duration of response determined via response evaluation criteria in solid tumors (RECIST) v1.1 and immune-related RECIST, and pharmacokinetics. Immune biomarkers are being assessed by immunohistochemistry (IHC) and a comprehensive gene profiling panel using a NanoString platform.

Results

Enrollment of patients in the run-in cohort is pending. IHC assay validation for RORγ and other immune markers is complete. Results of safety, preliminary efficacy, and biomarker evaluation will be available for patients initially enrolled at the time of presentation.

Conclusions

The LYC-55716 safety profile and clinical activity as a monotherapy agent support investigation of L+P to treat patients with metastatic NSCLC.

Clinical trial identification

NCT03396497.

Legal entity responsible for the study

Lycera Corp.

Funding

Lycera Corp.

Editorial Acknowledgement

Autumn Kelly, MA, CMPP, of Simcoe Consultants, Inc, on behalf of Lycera Corp.

Disclosure

D.R. Camidge: Research funding: Takeda. S.M. Gadgeel: Advisory roles: Pfizer, Genentech/Roche, Ariad, AstraZeneca, Bristol-Myers Squibb, Abbvie; Speakers' bureau: AstraZeneca; Research funding: Merck; Research funding to institution: Pfizer, Merck, Genentech/Roche, Incyte, Millennium, AstraZeneca/MedImmune, Bristol-Myers Squibb, Halozyme, Acerta Pharma, ACEA Biosciences, Janssen Oncology, Novartis, Five Prime Therapeutics, OncoMed. H.J. Wilkins, G. Weems: Employee and shareholder: Lycera Corp. M. Johnson: Research funding to institution: OncoMed, BerGenBio, Lilly, EMD Serono, Kadmon, Janssen, Mirati Therapeutics, Genmab, Pfizer, AstraZeneca, StemCentRx, Novartis, Checkpoint Therapeutics, Array BioPharma, Regeneron, Merck, Hengrui Pharmaceutical, Lycera Corp., BeiGene, Tarveda Therapeutics, Loxo, Abbvie, Boehringer Ingelheim, Guardant Health, Foundation Medicine, Daiichi Sankyo, Sanofi, Mersana. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.